Replicel Life Sciences Inc
XTSX:RP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (1.5), the stock would be worth CA$0.01 (43% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2.6 | CA$0.02 |
0%
|
| 3-Year Average | 1.5 | CA$0.01 |
-43%
|
| Industry Average | 3.4 | CA$0.02 |
+32%
|
| Country Average | 2.7 | CA$0.02 |
+3%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
|
Replicel Life Sciences Inc
XTSX:RP
|
722.3k CAD | 2.6 | -15.9 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
958.5B USD | 132.2 | 3 973.8 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
173.9B USD | 3.4 | 25.5 | |
| US |
|
Danaher Corp
NYSE:DHR
|
127.8B USD | 2.4 | 34.3 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 6.8 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
299.9B CNY | 3.8 | 15.7 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
33.5B CHF | 3.8 | -120.2 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.7B USD | 4.7 | 25.2 | |
| US |
|
Waters Corp
NYSE:WAT
|
29.4B USD | 11.5 | 46 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.8B USD | 4.2 | 20 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26B USD | -1 088.9 | 29.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.6 |
| Median | 2.7 |
| 70th Percentile | 4.9 |
| Max | 1 402.4 |
Other Multiples
Replicel Life Sciences Inc
Glance View
RepliCel Life Sciences, Inc. is a regenerative medicine company, which engages in the development of autologous cell therapies that treat functional cellular deficits including chronic tendon injuries, androgenetic alopeci, and skin aging. The company is headquartered in Vancouver, British Columbia and currently employs 1 full-time employees. The company went IPO on 2012-09-29. The company is focused on developing autologous cell therapies that treat functional cellular deficits including chronic tendon injuries, androgenetic alopecia, and skin aging. Its product pipeline includes RCT-01 for Tendon Repair, RCS-01 for Skin Rejuvenation, RCH-01 Hair Growth and RCI-02 Dermal Injector Publication . RCT-01 is an autologous cell-based treatment utilizing non-bulbar dermal sheath cells isolated from the hair follicle for the treatment of chronic Achilles tendinopathy. RCS-01 is an autologous cell therapy being developed to rejuvenate aging or Ultraviolet (UV)-damaged skin. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCI-02 is a dermal injector designed to deliver a variety of injectable substances in and under the skin with a range of needle configurations.
